Haloperidol for the Treatment of Nausea and Vomiting in the ED

A Single Center, Randomized Controlled Prospective Double-blinded Trial Comparing Haloperidol to Standard Ondansetron Therapy for Control of Nausea and Vomiting in the Emergency Department

Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.

Inclusion Criteria:

• presenting to the emergency department with chief complaint of nausea or vomiting

Exclusion Criteria:

• abnormal blood pressure (>200/100mmHg or <90/40mmHg),
• fever (>100.4F),
• acute trauma,
• QT > 450ms on cardiac monitor,
• altered mental status (GCS < 15),
• chest pain,
• known allergy to haloperidol or ondansetron,
• Parkinson's disease,
• pregnancy or lactation,
• use of any antiemetic in the previous 8 hours,
• nausea and vomiting associated with vertigo,
• prisoners or any wards of the state.